drugset / Trial / NCT05068856
A Study of HRS2543 in Patients With Advanced Tumors
NaSingle-groupOpen-labelTreatment
Summary
To assess the safety and tolerability of HRS2543 in patients with advanced tumors and to determine the recommended phase II dose (RP2D) of HRS2543
Timeline
- Start
- 2021-12-28
- Primary completion
- 2024-05-15
- Completion
- 2024-05-15
Outcome
Outcome not reported
Stopped (Business): “R\&d strategy adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS2543 | Unknown | 25 mg | — |
| Subject | HRS2543 | Unknown | 75 mg | — |
| Subject | HRS2543 | Unknown | 150 mg | — |
| Subject | HRS2543 | Unknown | 300 mg | — |
| Subject | HRS2543 | Unknown | 450 mg | — |
Indications
No indication recorded.